---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031882"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:30:35.853048+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Imunon reports positive Phase 2 OS data for IMNN-001; net loss narrows in Q2 2024

## Summary
- Q2 net loss of $4.8M ($0.51/share) vs $5.6M ($0.61/share) in Q2 2023; operating expenses down 8%.
- Positive OVATION 2 topline: 11.1-month median OS improvement (HR=0.74) in ITT; 15.7-month gain in per-protocol (HR=0.64).
- Phase 3 study of IMNN-001 planned to start Q1 2025 after End-of-Phase 2 FDA meeting.
- Raised $10M gross ($9M net) in July 2024 registered direct offering; cash + investments $5.3M at June 30, funding into Q3 2025.
- IMNN-101 Phase 1 COVID booster trial enrolling; topline data expected by year-end 2024.

## SEC filing metadata
- accession: 0001493152-24-031882
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315224031882/0001493152-24-031882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315224031882/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031882
- JSON: https://secwatch.observer/filing/0001493152-24-031882.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031882.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.